HCV / Hepatitis

Infection with hepatitis B (HBV) can be challenging. What will patients accept in exchange for the chance of a functional care?

CDC report chronicles 20 incidents of HBV infection among recipients between 2014 and 2019.

New shot fills a vital need, given poor efficacy of earlier options, researchers say.

With its mRNA COVID-19 vaccine authorized, the company is employing the technology to take aim at a variety of pathogens.

Simplifying access to hepatitis C virus care, including decentralized community-based care and task shifting to non-specialists, could improve testing and treatment for patients in settings with limited resources.

Series completion rates were different among patient groups, the study authors observed.

COVID-19 has further highlighted the need for innovative models that minimize face-to-face contact in HCV treatment.

An investigational HCV vaccine induced immunologic response and was well tolerated, but did not protect against infection.

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

The presenting IDWeek author discusses the implication of promising phase 3 data for a new HBV vaccine.

A cross-specialty collaboration to mitigate inpatient cases of opioid use disorder has had early success; developers want to grow it.

A firsthand look into a Kentucky program that's initiated opioid use disorder care in recurring HIV, hepatitis C patients.

New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.

Study explores the antiviral mechanisms of C19orf66, an interferon-induced inhibitor.

The CDC is calling for all adults to get tested for hepatitis C after the annual rate of infections tripled between 2009 and 2019.

The 2 new recommendations are for HCV screening at least once for all adults aged 18 years or older and HCV screening for women during each pregnancy.

From 2013 to 2018, new HCV cases fell 68% among men living with HIV in 2 UK cities, London and Brighton.

How does sharing needles impact the risk for hepatitis C among people who inject drugs?

The FDA approved a combination therapy of sofosbuvir and velpatasvir to treat children with hepatitis C virus.

To assess available evidence and provide an update from the 2013 review, a team of investigators reviewed more than 80 studies featuring data from over 179,000 individuals.

PWID are unlikely to receive testing for HIV and hepatitis C, according to a new study that found that 8.5% were tested for HIV and 7.7% were tested for HCV within 1 year of a clinical encounter consistent with injection drug use.

Despite new treatment options with a lower theoretical risk, approximately 40% of patients with HCV experienced a drug-drug interaction.

Andrea L. Cox, MD, PhD, comments on the future of HCV vaccine development efforts in light of the 2019 trial which did not prevent chronic infection.

Minimal monitoring of patients receiving sofosbuvir-based therapy for hepatitis C virus resulted in equal cure rates at less cost than standard monitoring, a new study found.

Newer, more effective antivirals mean hearts from donors with HCV are a viable option for transplantation. Rising opioid-related deaths means there are more of these donors available.

Andrea L. Cox, MD, PhD, discusses some of the challenges in developing a vaccine for hepatitis C and details the results of a vaccine trial.

Andrea L. Cox, MD, PhD, compares the rates of hepatitis C and hepatitis B diagnoses since the start of the opioid epidemic.

Combining financial incentives and accelerated vaccine schedules may improve hepatitis B vaccination completion among people who inject drugs who are at high risk for the infection, according to a new study.

A literature meta-analysis determined the worldwide prevalence of hepatitis B virus in people living with HIV.

Observations about the body’s response to malaria infection can lead to new treatments for HIV and lupus, investigators believe.